Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal Dystrophy (INAD)

 Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal Dystrophy (INAD)

Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal Dystrophy (INAD)

Shots:

  • The EMA’s ODD is based on P-II/III study assessing RT001 in patients with INAD, a neurodegeneration associated with PLA2G6
  • EMA’s ODD is granted to the drug offering treatments for rare, devastating, fatal, and untreated diseases affecting fewer than 200,000 people or >200,000 persons
  • Retrotope’s RT001 is an oral deuterated polyunsaturated fatty acid (D-PUFA) working against PUFA to prevent cell death

Click here to read full press release/ article | Ref: Retrotope | Image: PRNewswire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post